About unicycive therapeutics inc - UNCY
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
UNCY At a Glance
Unicycive Therapeutics, Inc.
4300 El Camino Real
Los Altos, California 94022
| Phone | 1-650-351-4495 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -36,729,000.00 | |
| Sector | Health Technology | Employees | 22 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
UNCY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 12.167 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.878 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.028 |
UNCY Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,669,500.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
UNCY Liquidity
| Current Ratio | 1.283 |
| Quick Ratio | 1.283 |
| Cash Ratio | 1.084 |
UNCY Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -160.182 |
| Return on Equity | -2,028.106 |
| Return on Total Capital | -447.696 |
| Return on Invested Capital | -1,746.92 |
UNCY Capital Structure
| Total Debt to Total Equity | 10.402 |
| Total Debt to Total Capital | 9.422 |
| Total Debt to Total Assets | 2.441 |
| Long-Term Debt to Equity | 1.574 |
| Long-Term Debt to Total Capital | 1.426 |